EXEL vs. ALNY, BIIB, UTHR, NBIX, INCY, BMRN, EXAS, RGEN, HALO, and MDGL
Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.
Exelixis vs.
Exelixis (NASDAQ:EXEL) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings, risk and community ranking.
Exelixis has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.
Alnylam Pharmaceuticals received 532 more outperform votes than Exelixis when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 68.63% of users gave Exelixis an outperform vote.
Exelixis has a net margin of 22.43% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Exelixis' return on equity of 20.99% beat Alnylam Pharmaceuticals' return on equity.
In the previous week, Exelixis had 22 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 42 mentions for Exelixis and 20 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.76 beat Exelixis' score of 0.61 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.
Exelixis currently has a consensus price target of $35.50, indicating a potential downside of 1.93%. Alnylam Pharmaceuticals has a consensus price target of $298.61, indicating a potential upside of 21.25%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.
85.3% of Exelixis shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 2.9% of Exelixis shares are held by insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Exelixis has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Summary
Exelixis beats Alnylam Pharmaceuticals on 10 of the 18 factors compared between the two stocks.
Get Exelixis News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exelixis Competitors List
Related Companies and Tools
This page (NASDAQ:EXEL) was last updated on 1/21/2025 by MarketBeat.com Staff
